Comparative in vitro antipseudomonal activity of ceftolozane/tazobactam against Pseudomonas aeruginosa isolates from children with cystic fibrosis.

Document Type

Article

Publication Date

4-2023

Identifier

DOI: 10.1016/j.diagmicrobio.2023.115904

Abstract

This study evaluated the in vitro activity of Ceftolozane/tazobactam (C/T) vs 10 comparator agents against Pseudomonas aeruginosa isolates obtained from clinical respiratory samples from pediatric patients with cystic fibrosis at three hospitals during 2015 to 2020. Antimicrobial susceptibility testing was performed using microbroth dilution technique with custom prepared Sensititre® MIC plates. MICs were determined via Sensititre Vizion® system and results were interpreted using current CLSI and EUCAST (2022) breakpoint criteria. C/T was the most potent agent as compared with other antipseudomonal drugs against 291 isolates with MIC50 = 1 μg/mL and MIC90 = 2 μg/mL with percent susceptibility as 95.2%. C/T remained active against majority of ß-lactam non-susceptible isolates; percent susceptibility ranging from 61.2% to 80% including 65.9% ceftazidime non-susceptible isolates. C/T had high activity against P. aeruginosa from 3 geographically diverse pediatric medical centers. Study results suggest that C/T may be used as a potential therapeutic option for treating pediatric patients with CF.

Journal Title

Diagnostic microbiology and infectious disease

Volume

105

Issue

4

First Page

115904

Last Page

115904

MeSH Keywords

Humans; Child; Pseudomonas aeruginosa; Anti-Bacterial Agents; Cystic Fibrosis; Enterobacteriaceae; Penicillanic Acid; Enterobacteriaceae Infections; Pseudomonas Infections; Tazobactam; Cephalosporins; Microbial Sensitivity Tests; Drug Resistance, Multiple, Bacterial

Keywords

Antimicrobial susceptibility; MIC; ceftolozane/tazobactam; cystic fibrosis; pediatric, Pseudomonas

Link to Full Text
Library Record

Share

COinS